Patents by Inventor Gary R. Brownlee

Gary R. Brownlee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20140328828
    Abstract: The present invention relates generally to treatment and prophylactic protocols for cellular disease or disorders, such as diseases and disorders associated with abnormal cellular proliferation. More particularly, the present invention provides uses of compositions comprising therapeutic antibodies and hyaluronan in the treatment or prophylaxis of cellular diseases and disorders.
    Type: Application
    Filed: December 4, 2013
    Publication date: November 6, 2014
    Applicant: ALCHEMIA ONCOLOGY PTY LIMITED
    Inventors: Tracey J. BROWN, Gary R. BROWNLEE
  • Patent number: 8623354
    Abstract: The present invention relates generally to treatment and prophylactic protocols for cellular diseases or disorders, such as diseases and disorders associated with abnormal cellular proliferation. More particularly, the present invention provides compositions comprising therapeutic antibodies and hyaluronan and their use in the treatment or prophylaxis of cellular diseases and disorders.
    Type: Grant
    Filed: September 4, 2006
    Date of Patent: January 7, 2014
    Assignee: Alchemia Oncology Pty Limited
    Inventors: Tracey J. Brown, Gary R. Brownlee
  • Patent number: 8460658
    Abstract: The present invention relates generally to the modulation of hyaluronan (HA) synthesis and degradation. The present invention further contemplates modulation of cellular proliferation, useful in the prophylaxis and/or treatment of inflammatory disorders including hyperproliferative conditions, such as but not limited to, cancer and psoriasis. The present invention is directed to compounds, agents, pharmaceutically active agents, medicaments, therapeutics, actives, drugs and the like which specifically target a portion of HAS which is accessible to the extracellular environment in malignant or inflammatory or proliferative cells but which portion is not accessible to the external environment in “normal” cells. A “normal” cell in this instance is a non-malignant, inflammatory or proliferative cell.
    Type: Grant
    Filed: June 13, 2011
    Date of Patent: June 11, 2013
    Assignee: Alchemia Oncology Pty Limited
    Inventors: Tracey J. Brown, Gary R. Brownlee
  • Publication number: 20120009193
    Abstract: The present invention relates generally to the modulation of hyaluronan (HA) synthesis and degradation. More particularly, the present invention provides compositions and methods for modulating the expression of genetic material encoding HA synthase (HAS) and other enzymes or receptors primarily involved in hyaluronan metabolism; or modulating the proteins that synthesise or degrade hyaluronan including HAS function or activity. The compositions include or comprise nucleic acid molecules and interactive molecules such as antibodies and small molecule inhibitors and HAS substrate analogs. The present invention further contemplates modulation of cellular proliferation, useful in the prophylaxis and/or treatment of inflammatory disorders including hyperproliferative conditions, such as but not limited to, cancer and psoriasis.
    Type: Application
    Filed: June 13, 2011
    Publication date: January 12, 2012
    Applicant: Alchemia Oncology Pty Limited
    Inventors: Tracey J. Brown, Gary R. Brownlee
  • Patent number: 7985844
    Abstract: Modulation of Hyaluronan (HA) synthesis and degradation is disclosed by compounds and compositions that are capable of reducing the level of hyaluronan synthase (HAS) or hyaluronidase (HYAL) or the function or activity of HAS or HYAL. The compounds and compositions can also inhibit the expression of genetic material encoding these enzymes. The compounds and compositions comprise nucleic acid molecules and interactive molecules such as antibodies, small molecule inhibitors and substrate analogs of HAS and HYAL. The compounds and compositions are useful in the prophylaxis and/or treatment of inflammatory disorders including hyperproliferative conditions, such as but not limited to, cancer and psoriasis.
    Type: Grant
    Filed: December 15, 2009
    Date of Patent: July 26, 2011
    Assignee: Alchemia Oncology Pty Limited
    Inventors: Tracey J. Brown, Gary R. Brownlee
  • Patent number: 7662929
    Abstract: Modulation of Hyaluronan (HA) synthesis and degradation is disclosed by compounds and compositions that are capable of reducing the level of hyaluronan synthase (HAS) or hyaluronidase (HYAL) or the function or activity of HAS or HYAL. The compounds and compositions can also inhibit the expression of genetic material encoding these enzymes. The compounds and compositions comprise nucleic acid molecules and interactive molecules such as antibodies, small molecule inhibitors and substrate analogs of HAS and HYAL. The compounds and compositions are useful in the prophylaxis and/or treatment of inflammatory disorders including hyperproliferative conditions, such as but not limited to, cancer and psoriasis.
    Type: Grant
    Filed: October 11, 2004
    Date of Patent: February 16, 2010
    Assignee: Alchemia Oncology Pty Limited
    Inventors: Tracey J. Brown, Gary R. Brownlee